scholarly journals Intravesical RNA activation—a new treatment concept

2012 ◽  
Vol 9 (10) ◽  
pp. 546-546
Author(s):  
Sarah Payton
Keyword(s):  
Treatment Concept ◽  
Rna Activation ◽  
New Treatment

scholarly journals Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia

Blood ◽  
2012 ◽  
Vol 119 (7) ◽  
pp. 1717-1725 ◽  
Author(s):  
Katie O'Callaghan ◽  
Lydia Lee ◽  
Nga Nguyen ◽  
Mo-Ying Hsieh ◽  
Nicole C. Kaneider ◽  
...  
Keyword(s):  
Lymphocytic Leukemia ◽  
Response To Treatment ◽  
Treatment Concept ◽  
Hematologic Neoplasms ◽  
Cxcr4 Signaling ◽  
Lymphoid Malignancies ◽  
Cell Penetrating ◽  
Apoptotic Effect ◽  
New Treatment ◽  
Intracellular Loops

Abstract The chemokine receptor CXCR4, which normally regulates stromal stem cell interactions in the bone marrow, is highly expressed on a variety of malignant hematologic cells, including lymphoma and lymphocytic leukemias. A new treatment concept has arisen wherein CXCR4 may be an effective therapeutic target as an adjunct to treatment of hematologic neoplasms with chemo- and immunotherapy. In the present study, we developed pepducins, cell-penetrating lipopeptide antagonists of CXCR4, to interdict CXCL12-CXCR4 transmembrane signaling to intracellular G-proteins. We demonstrate that pepducins targeting the first (i1) or third (i3) intracellular loops of CXCR4 completely abrogate CXCL12-mediated cell migration of lymphocytic leukemias and lymphomas. Stromal-cell coculture protects lymphoma cells from apoptosis in response to treatment with the CD20-targeted Ab rituximab. However, combination treatment with CXCR4 pepducins and rituximab significantly increases the apoptotic effect of rituximab. Furthermore, treatment of mice bearing disseminated lymphoma xenografts with pepducins alone or in combination with rituximab significantly increased their survival. These data demonstrate that CXCL12-CXCR4 signaling can be effectively inhibited by cell-penetrating pepducins, which represents a potential new treatment strategy for lymphoid malignancies.

Magnetic nanoparticles for magnetic drug targeting

2015 ◽  
Vol 60 (5) ◽  
Author(s):  
Stefan Lyer ◽  
Raminder Singh ◽  
Rainer Tietze ◽  
Christoph Alexiou
Keyword(s):  
Magnetic Nanoparticles ◽  
Side Effects ◽  
Drug Targeting ◽  
Superparamagnetic Iron Oxide ◽  
Magnetic Drug Targeting ◽  
Oxide Nanoparticles ◽  
Treatment Concept ◽  
Substantial Progress ◽  
New Treatment ◽  
Tumor Area

AbstractNanomedicine and superparamagnetic iron oxide nanoparticles (SPIONs) are thought to have an important impact on medicine in the future. Especially in cancer therapy, SPIONs offer the opportunity of improving the effectivity of the treatment and reduce side effects by magnetic accumulation of SPION-bound chemotherapeutics in the tumor area. Although still some challenges have to be overcome, before the new treatment concept of magnetic drug targeting will reach the patients, substantial progress has been made, and promising results were shown in the last years.

The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care

2018 ◽  
Vol 125 (10) ◽  
pp. 1461-1472 ◽  
Author(s):  
Odette Fründt ◽  
Tina Mainka ◽  
Beate Schönwald ◽  
Bianca Müller ◽  
Polina Dicusar ◽  
...  
Keyword(s):  
Outpatient Care ◽  
Treatment Concept ◽  
Day Clinic ◽  
New Treatment

Results of a New Treatment Concept for Concomitant Lesion of Medial Collateral Ligament in Patients with Rupture of Anterior Cruciate Ligament

2016 ◽  
Vol 30 (07) ◽  
pp. 652-658 ◽  
Author(s):  
Jochen Paul ◽  
Maximilian Haenle ◽  
Jannes Sailer ◽  
Geert Pagenstert ◽  
Lutz Wehren ◽  
...  
Keyword(s):  
Anterior Cruciate Ligament ◽  
Medial Collateral Ligament ◽  
Cruciate Ligament ◽  
Acl Rupture ◽  
Treatment Concept ◽  
Collateral Ligament ◽  
Term Outcome ◽  
Anterior Cruciate ◽  
New Treatment

AbstractAnteromedial knee injury with rupture of anterior cruciate ligament (ACL) and concomitant lesion of medial collateral ligament (MCL) is common in athletes. No standardized treatment concept can be found within the literature. This study presents results of a new treatment concept for concomitant MCL lesions in patients with ACL rupture. In this study, 67 recreational athletes with ACL injury and concomitant MCL lesion were treated according to a distinct treatment concept. Patients were classified in six different types of concomitant MCL lesion depending on grade of MCL lesion and presence of anteromedial rotatory instability (AMRI). Final classification and surgical indication were determined 6 weeks posttraumatic. All patients received ACL reconstruction. MCL was treated by surgical or conservative regime due to type of concomitant MCL lesion. International Knee Documentation Committee (IKDC), AMRI, and Lysholm scores were evaluated both preoperatively and after 6 weeks, 16 weeks, 12 months, and 18 months postoperatively. All patients could be uniquely classified and treated according to the introduced treatment concept. AMRI was verifiable in patients with grade II and III MCL lesions. All patients showed good to excellent clinical results at the follow-up examinations. In all 67 patients (100%), the findings were graded as normal or nearly normal according to the IKDC knee examination form. Lysholm score averaged 93.9 at final follow-up. The introduced treatment concept showed good results on short-term outcome and provides a sufficient treatment strategy for concomitant MCL lesions in athletes with ACL rupture.

scholarly journals Mild bronchial asthma: a modern treatment concept

2019 ◽  
pp. 29-36
Author(s):  
A. V. Emel’yanov ◽  
E. V. Leshenkova ◽  
G. R. Sergeyeva
Keyword(s):  
Bronchial Asthma ◽  
Clinical Symptoms ◽  
Low Doses ◽  
Treatment Concept ◽  
Significant Cost ◽  
Cost Of Treatment ◽  
New Treatment ◽  
Inhaled Glucocorticoids ◽  
Mild Bronchial Asthma

Mild bronchial asthma (BA) occurs in 50–75% of patients with this disease. It is characterized by clinical symptoms that are controlled by low doses of inhaled glucocorticoids (IGCS) or anti-leukotriene drugs. Mild BA reduces the quality of life of patients, is accompanied by the development of severe, in some cases fatal exacerbations, and is characterized by a significant cost of treatment. One of the main problems in the management of patients with this disease is their low adherence to IGCS treatment and the excessive use of short-acting 2-adrenomimetic agents. Several clinical studies have shown that the use of a combination of budesonide/formoterol (Symbicort® Turbuhaler®) in an «as needed» mode reduces the incidence of severe exacerbations of mild BA as well as low doses of budesonide, and is characterized by a lower cumulative dose of this glucocorticoid. The results obtained were the basis for the creation of a new treatment concept, which gives preference to the combination of IGCS / formoterol «as needed» in mild BA as a supporting therapy, and for the management of symptoms of the disease.

Diffusing Alpha Emitters Radiation Therapy (DART) Brachytherapy for Recurrent and Radio-Resistant Head and Neck and Skin Cancer: A New Treatment Concept

Brachytherapy ◽  
2019 ◽  
Vol 18 (3) ◽  
pp. S38
Author(s):  
Aron Popovtzer ◽  
Eli Rosenfeld ◽  
Aviram Mizrachy ◽  
Ran Ben Hur ◽  
Salvatore Bellia ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Skin Cancer ◽  
Head And Neck ◽  
Treatment Concept ◽  
Alpha Emitters ◽  
New Treatment
Sign in / Sign up

Export Citation Format

Share Document